HER2, also a well-established therapeutic target, is amplified/overexpressed in 12%–20% of breast cancers and 7%–25% of gastroesophageal cancers, for which trastuzumab-based anti-HER2 therapy has transformed the standard of care with a demonstrated survival benefit (3). This evidence concerns the gene ERBB2 and breast carcinoma.